Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes.
Publication/Presentation Date
3-1-2019
Abstract
Adoptive immunotherapy has shown efficacy in patients with relapsed/refractory acute myelogenous leukemia (AML). We conducted a prospective evaluation of cord blood (CB)-based adoptive cell therapy following salvage chemotherapy in patients with AML or myelodysplastic syndrome (MDS) and describe the safety and early outcomes of this approach. To enhance the antileukemic effect, we selected CB units (CBUs) with a shared inherited paternal antigen (IPA) and/or noninherited maternal antigen (NIMA) match with the recipients. Furthermore, the CBUs had total nucleated cell (TNC) dose
Volume
25
Issue
3
First Page
466
Last Page
473
ISSN
1523-6536
Published In/Presented At
Gergis, U., Frenet, E. M., Shore, T., Mayer, S., Phillips, A., Hsu, J. M., Roboz, G., Ritchie, E., Scandura, J., Lee, S., Desai, P., Samuel, M., Ball, J., Blanco, A., Romeo, C., Albano, M. S., Dobrila, L., Scaradavou, A., & van Besien, K. (2019). Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 25(3), 466–473. https://doi.org/10.1016/j.bbmt.2018.11.002
Disciplines
Medicine and Health Sciences
PubMedID
30414955
Department(s)
Department of Medicine, Hematology-Medical Oncology Division, Lehigh Valley Topper Cancer Institute
Document Type
Article